436 related articles for article (PubMed ID: 19129749)
1. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus.
Komoroski B; Vachharajani N; Feng Y; Li L; Kornhauser D; Pfister M
Clin Pharmacol Ther; 2009 May; 85(5):513-9. PubMed ID: 19129749
[TBL] [Abstract][Full Text] [Related]
2. A Randomized Crossover Trial of Mixed Meal Tolerance Test Response in People with Type 1 Diabetes on Insulin Pump Therapy and YG1699 or Dapagliflozin.
Lapuerta P; Urbina S; He J; Wittle A; Li C; Li T; Wang H; Hompesch M
Clin Pharmacol Ther; 2024 Jun; 115(6):1383-1390. PubMed ID: 38456487
[TBL] [Abstract][Full Text] [Related]
3. Analysing uric acid levels to assess the effectiveness of dapagliflozin.
Rajasekar R; Sundaram SM; Raj CP; Poovitha M; Kumar JS
Clin Nutr ESPEN; 2024 Feb; 59():81-88. PubMed ID: 38220410
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin induced hypernatremia via osmotic diuresis: a case report.
Sugiyama J; Ryuge A; Mitsubayashi K; Ito M; Matsumoto N; Takeuchi R; Azuma K; Hachiya A; Asano M; Nakamura T
CEN Case Rep; 2024 Feb; 13(1):9-13. PubMed ID: 37074627
[TBL] [Abstract][Full Text] [Related]
5. Impact of voglibose on the pharmacokinetics of dapagliflozin in Japanese patients with type 2 diabetes.
Imamura A; Kusunoki M; Ueda S; Hayashi N; Imai Y
Diabetes Ther; 2013 Jun; 4(1):41-9. PubMed ID: 23307267
[TBL] [Abstract][Full Text] [Related]
6. The impact of dapagliflozin on glucose excursions related to early proatherogenic derangement in the aortic wall.
Stelmaszyk A; Wesołowska A; Pomieczyńska K; Iskakova S; Frydrychowicz M; Dworacki G; Dworacka M
Saudi Pharm J; 2018 Dec; 26(8):1192-1198. PubMed ID: 30510471
[TBL] [Abstract][Full Text] [Related]
7. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
[TBL] [Abstract][Full Text] [Related]
8. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.
Ferrannini E; Ramos SJ; Salsali A; Tang W; List JF
Diabetes Care; 2010 Oct; 33(10):2217-24. PubMed ID: 20566676
[TBL] [Abstract][Full Text] [Related]
9. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.
Bolinder J; Ljunggren Ö; Kullberg J; Johansson L; Wilding J; Langkilde AM; Sugg J; Parikh S
J Clin Endocrinol Metab; 2012 Mar; 97(3):1020-31. PubMed ID: 22238392
[TBL] [Abstract][Full Text] [Related]
10. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
[TBL] [Abstract][Full Text] [Related]
11. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.
Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
Diabetes Obes Metab; 2011 Oct; 13(10):928-38. PubMed ID: 21672123
[TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial.
Wilding JP; Woo V; Soler NG; Pahor A; Sugg J; Rohwedder K; Parikh S;
Ann Intern Med; 2012 Mar; 156(6):405-15. PubMed ID: 22431673
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin.
Bolinder J; Ljunggren Ö; Johansson L; Wilding J; Langkilde AM; Sjöström CD; Sugg J; Parikh S
Diabetes Obes Metab; 2014 Feb; 16(2):159-69. PubMed ID: 23906445
[TBL] [Abstract][Full Text] [Related]
14. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial.
Nauck MA; Del Prato S; Meier JJ; Durán-García S; Rohwedder K; Elze M; Parikh SJ
Diabetes Care; 2011 Sep; 34(9):2015-22. PubMed ID: 21816980
[TBL] [Abstract][Full Text] [Related]
15. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial.
Henry RR; Murray AV; Marmolejo MH; Hennicken D; Ptaszynska A; List JF
Int J Clin Pract; 2012 May; 66(5):446-56. PubMed ID: 22413962
[TBL] [Abstract][Full Text] [Related]
16. Long-term glycaemic response and tolerability of dapagliflozin versus a sulphonylurea as add-on therapy to metformin in patients with type 2 diabetes: 4-year data.
Del Prato S; Nauck M; Durán-Garcia S; Maffei L; Rohwedder K; Theuerkauf A; Parikh S
Diabetes Obes Metab; 2015 Jun; 17(6):581-590. PubMed ID: 25735400
[TBL] [Abstract][Full Text] [Related]
17. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial.
Bailey CJ; Gross JL; Hennicken D; Iqbal N; Mansfield TA; List JF
BMC Med; 2013 Feb; 11():43. PubMed ID: 23425012
[TBL] [Abstract][Full Text] [Related]
18. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus.
Kasichayanula S; Chang M; Hasegawa M; Liu X; Yamahira N; LaCreta FP; Imai Y; Boulton DW
Diabetes Obes Metab; 2011 Apr; 13(4):357-65. PubMed ID: 21226818
[TBL] [Abstract][Full Text] [Related]
20. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.
Kohan DE; Fioretto P; Tang W; List JF
Kidney Int; 2014 Apr; 85(4):962-71. PubMed ID: 24067431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
